- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06742801
Onyx™ Liquid Embolic IDE klinisk studie
PELE IDE klinisk studie, perifer Onyx™ flytande embolisk säkerhet och effektiviteten av Onyx™ LES för embolisering av arteriell blödning i den perifera kärlen
The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a pivotal, prospective, multi-center, non-randomized, single arm study. This study will enroll patients with active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by investigator. In this study, peripheral vasculature is defined as outside of the brain and heart.
Approximately 135 subjects will be consented to achieve 119 enrolled at up to 25 sites in the US.
This study will have two visits post-index procedure including hospital discharge visit and 30-day follow-up visit. Reintervention visits will be captured through 30 days post-index procedure.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Liza Marie
- Telefonnummer: 7072172314
- E-post: liza.marie@medtronic.com
Studera Kontakt Backup
- Namn: Janki Shah
- Telefonnummer: 7322662503
- E-post: janki.shah@medtronic.com
Studieorter
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85054
- Rekrytering
- Mayo Clinic
-
Kontakt:
- Debbie Ryan
- Telefonnummer: 480-342-1208
- E-post: ryan.debra29@mayo.edu
-
Huvudutredare:
- Sadeer Alzubaidi, MD
-
Kontakt:
- Yahaira Parker
-
-
California
-
Irvine, California, Förenta staterna, 92627
- Rekrytering
- University of California, Irvine
-
Kontakt:
- Nadine Jaoudeh, MD
- E-post: nadine@hs.uci.edu
-
Kontakt:
- Kimberly Padilla
- E-post: kpadill6@hs.uci.edu
-
Los Angeles, California, Förenta staterna, 90095
- Rekrytering
- University of California Los Angeles
-
Kontakt:
- Renato Escobar
- E-post: raescobar@mednet.ucla.edu
-
Huvudutredare:
- Jessica Stewart, MD
-
Palo Alto, California, Förenta staterna, 94304
- Rekrytering
- Stanford Medical Center
-
Kontakt:
- Andrew Picel, MD
-
Kontakt:
- Abigail Bond
- E-post: abond02@stanford.edu
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Rekrytering
- UCHealth University of Colorado Hospital
-
Kontakt:
- Alejandra Aguilar, MPH
- E-post: alejandra.aguilar@cuanschutz.edu
-
Huvudutredare:
- Eduardo Bent Robinson, MD
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06510
- Rekrytering
- Yale New Haven
-
Kontakt:
- Patricia Fugal
- E-post: patricia.fugal@yale.edu
-
Kontakt:
- Angelo Marino, MD
- E-post: angelo.marino@yale.edu
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- Rekrytering
- University of Chicago
-
Kontakt:
- Tiana Jackson
- E-post: tiana.jackson@bsd.uchicago.edu
-
Huvudutredare:
- Brian Funaki, MD
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242
- Rekrytering
- University of Iowa Hospitals and Clinics
-
Huvudutredare:
- Michael Hummel, MD
-
Kontakt:
- Victoria Mendoza
- E-post: victoria-mendoza@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Masschusetts General Hospital
-
Kontakt:
- Vincent Wu, MD
- E-post: vwu3@mgh.harvard.edu
-
Kontakt:
- Justin Hill
- E-post: jhill43@mgh.harvard.edu
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68124
- Rekrytering
- CHI Health Creighton University Medical Center-Bergan-Mercy
-
Kontakt:
- Janice Mitchel
- Telefonnummer: 402-619-9402
- E-post: jan.mitchell@commonspirit.org
-
Huvudutredare:
- Patrick Harty
-
-
New Jersey
-
Newark, New Jersey, Förenta staterna, 07103
- Rekrytering
- Rutgers New Jersey Medical School
-
Huvudutredare:
- Abhishek Kumar, MD
-
Kontakt:
- Saharsh Patel
- E-post: ssp186@gsbs.rutgers.edu
-
-
New York
-
Albany, New York, Förenta staterna, 12208
- Rekrytering
- Albany Medical Center
-
Kontakt:
- Nancy Spencer, NP
- E-post: spencen@amc.edu
-
Kontakt:
- Gary Siskin, MD
- E-post: sisking@amc.edu
-
New York, New York, Förenta staterna, 10029
- Rekrytering
- The Mount Sinai
-
Kontakt:
- Rajesh Patel, MD
- E-post: rajesh.patel@mountsinai.org
-
Kontakt:
- Aaron Greenberg
- E-post: aaron.greenberg@mountsinai.org
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- Rekrytering
- University of North Carolina at Chapel Hill
-
Huvudutredare:
- Nima Kokabi, MD
-
Kontakt:
- Adriana Delgado
- E-post: adriana_delgado@med.unc.edu
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44106
- Rekrytering
- University Hospitals Cleveland Medical Center
-
Kontakt:
- Lauren Hahn
- E-post: lauren.hahn@uhhospitals.org
-
Huvudutredare:
- Salim Abboud, MD
-
Columbus, Ohio, Förenta staterna, 43210
- Rekrytering
- The Ohio State University
-
Kontakt:
- Mina Makary, MD
-
Kontakt:
- Gage Spears
- E-post: gage.spears@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15237
- Rekrytering
- University of Pittsburgh Medical Center
-
Huvudutredare:
- Paula Novelli, MD
-
Kontakt:
- Suzanne Burdin
- E-post: burdins@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37212
- Rekrytering
- Vanderbilt University Medical Center
-
Kontakt:
- Celia Nunez
- Telefonnummer: 615-322-4559
- E-post: celia.m.nunez@vumc.org
-
Huvudutredare:
- Anthony Borgmann, MD
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75235
- Rekrytering
- Univ Of Texas Southwestern
-
Huvudutredare:
- Sanjeeva Kalva, MD
-
Kontakt:
- Camille Harry
- Telefonnummer: 214-648-8986
- E-post: camille.harry@utsouthwestern.edu
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- The University of Texas Health Science Center at Houston
-
Kontakt:
- Praneeth Nadimpalli
- E-post: praneeth.v.nadimpalli@uth.tmc.edu
-
Kontakt:
- Lauren McGuire, RN
- E-post: lauren.c.mcguire@uth.tmc.edu
-
Huvudutredare:
- Rodrick Zvavanjanja, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Patient is ≥ 22 years old.
-
Active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by the investigator.
In this study, peripheral vasculature is defined as outside the brain and heart.
-
Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.
-
Life expectancy of >30 days, in the opinion of the investigator at the time of enrollment.
-
Target treatment area is free from prior embolization treatment.
Exclusion Criteria:
- Pregnant or breastfeeding.
- Symptoms of active infection.
- Patient is known to be participating in the study of an investigational drug, biologic, or device.
- Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.
- Known allergy to components of Onyx™.
- Target vasculature unsuitable for the delivery of Onyx™ based upon physician assessment.
- More than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment with Onyx LES
Device; embolization with liquid embolic |
The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Freedom from Arterial Hemorrhage
Tidsram: Through 30 days post-index procedure
|
Freedom from arterial hemorrhage in all target location(s) after treatment with Onyx™ LES at the index procedure without re-embolization or any other intervention at the target location(s) due to persistent or recurrent hemorrhage through 30 days. Freedom from arterial hemorrhage where an arterial hemorrhage event is defined as a type 3 or greater BARC bleeding criteria as assessed by the Clinical Events Committee (CEC) through 30 days. |
Through 30 days post-index procedure
|
|
Freedom from System-related Major Adverse Events (MAE)
Tidsram: Through 30 days post-index procedure
|
The primary safety endpoint is defined as freedom from system-related Major Adverse Events (MAE) through 30 days after the point of enrollment as assessed by the CEC. |
Through 30 days post-index procedure
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Procedural Success
Tidsram: At the completion of the index procedure
|
successful delivery and deployment of Onyx™ to the target location without non-target embolization or Onyx™ cast migration and the successful removal of the delivery system at the completion of the index procedure. |
At the completion of the index procedure
|
|
Technical Success
Tidsram: At the completion of the index procedure
|
Technical Success is defined as absence of angiographic signs of bleeding after Onyx ™ embolization at each target location based on core lab assessment. |
At the completion of the index procedure
|
|
Reintervention
Tidsram: Through 30 days post-index procedure
|
Reintervention is defined as the number of additional procedures needed to treat the target location(s) embolized with Onyx™ through 30 days following the index procedure. |
Through 30 days post-index procedure
|
|
Transfusions
Tidsram: Through 30 days post-index procedure
|
Transfusions defined as the number of blood transfusions required post-index procedure through 30 days will use blood transfusions starting after the removal of the delivery system. The number of blood units used for each transfusion will also be collected. |
Through 30 days post-index procedure
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Ancillary Endpoint
Tidsram: Through index procedure
|
Duration of the index procedure |
Through index procedure
|
|
Ancillary Endpoint
Tidsram: Through 30 days post-index procedure
|
Length of hospitalization, post-index procedure |
Through 30 days post-index procedure
|
|
Ancillary Endpoint
Tidsram: Through 30 days post-index procedure
|
Tabulate adjunctive use of other types of embolic agents to treat target locations at index procedure and reinterventions |
Through 30 days post-index procedure
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Osman Ahmed, MD, University of Chicago
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MDT21044
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .